Deutsche Bank's research report on Retrophin, a biotechnology company, includes a financial analysis and valuation update. Retrophin plans to sell a rare pediatric priority review voucher to Sanofi for $245M, with payments spread over 2015-2017. The report raises the target price to $52, reiterating a 'Buy' rating. The analysis includes a DCF valuation, financial metrics, and risk factors. The report also discloses Deutsche Bank's potential conflicts of interest and regulatory disclosures.
documents/EFTA01192826.pdf
{}